S5G4T-1 + S5G4T-2

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Papulopustular Rosacea

Conditions

Papulopustular Rosacea

Trial Timeline

Jun 21, 2018 → Jun 10, 2019

About S5G4T-1 + S5G4T-2

S5G4T-1 + S5G4T-2 is a phase 3 stage product being developed by Sol-Gel Technologies for Papulopustular Rosacea. The current trial status is completed. This product is registered under clinical trial identifier NCT03564119. Target conditions include Papulopustular Rosacea.

What happened to similar drugs?

3 of 12 similar drugs in Papulopustular Rosacea were approved

Approved (3) Terminated (1) Active (8)

Hype Score Breakdown

Clinical
17
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT03564119Phase 3Completed
NCT03448939Phase 3Completed

Competing Products

18 competing products in Papulopustular Rosacea

See all competitors
ProductCompanyStageHype Score
DFD-29 + Doxycycline + PlaceboDr. Reddy's LaboratoriesPhase 3
37
DFD-29 + Doxycycline + PlaceboDr. Reddy's LaboratoriesPhase 3
37
Lotilaner Gel, 2.0%Tarsus PharmaceuticalsPhase 2
29
Deucravacitinib + PlaceboBristol Myers SquibbPhase 2
27
Topical Dapsone 5% Gel + oral antibioticsBristol Myers SquibbPhase 3
40
Azelaic acid (Finacea, BAY39-6251) + Metronidazole (Metrogel) + Doxycycline (Oracea)BayerApproved
40
Azelaic Acid foam 15%BayerApproved
40
Azelaic acid + Vehicle foamBayerPhase 2
32
Azelaic acid foam 15% + Vehicle foamBayerPhase 2
32
azelaic acid 15% gel + azelaic acid 15% gelBayerApproved
40
Azelaic Acid Foam + Azelaic Acid GelBayerPhase 1
26
Azelaic acid foam, 15% (BAY39-6251) + Vehicle foamBayerPhase 3
37
Encapsulated Benzoyl Peroxide CreamSol-Gel TechnologiesPhase 1
19
S5G4T-1Sol-Gel TechnologiesPhase 3
22
S5G4T-1 + S5G4T-2Sol-Gel TechnologiesPhase 3
30
FMX103 minocycline foam 1.5% + Vehicle foamVyne TherapeuticsPhase 3
30
FMX103 1.5%Vyne TherapeuticsPhase 3
30
FMX103 minocycline foam 1.5% + Vehicle foamVyne TherapeuticsPhase 3
30